

EuroSIDA Newsletter

September 2015



ANNOUNCEMENTS

Dear EuroSIDA Study Investigators,

The staff at the EuroSIDA coordinating centre sends you many autumn greetings and we kindly thank you for your excellent work and continued contribution to the EuroSIDA study. Below, please find an update on the EuroSIDA study.

EACS 2015

We hope to see as many of you as possible at the

**EuroSIDA investigator meeting
at the 15th European AIDS conference in Barcelona
Friday the 23 October 7.30-8.30am
In the conference center room 129+130**

Please confirm your participation, if you have not already done so, to eurosidarigshospitalet@regionh.dk

EACS presentations

EuroSIDA will be represented at EACS with 3 oral and 6 poster presentations! Congratulations to all EuroSIDA investigators!

- Where is the Greatest Impact of Uncontrolled HIV Infection on Clinical Disease Progression. **PS8/6**
- Prostate-specific Antigen (PSA) Testing Patterns for Prostate Cancer (PCa) in HIV+ Men. Does One Size Fit All? **PS5/5**
- Trends in incidence and risk factors for hepatocellular carcinoma and other liver events in HIV and hepatitis C virus co-infected individuals from 2001 to 2014: a multi-cohort study. **PS7/2**
- HIV/HCV-coinfection across Europe. **PE13/23**
- Uptake of Tenofovir-based Combination Antiretroviral Therapy (cART) among HIV/HBV Co-infected Patients in the EuroSIDA Study. **PE13/4**
- Comparison of the Risk of Resistance Accumulation According to ART Switching Strategies after Virological Failure >200 Copies/mL to First cART Using the g-computation Procedure. **PE9/11**
- Inter-country variability on the degree of ART-induced HIV-RNA suppression. **PE8/71.**
- Long-term virological outcomes of ART-experienced patients receiving Raltegravir in a large European cohort study. **PE8/33**
- Incidence of cancer in individuals treated with raltegravir-based and non-raltegravir-based cART regimens. **PE11/9**

EuroSIDA dataset 42

The deadline for completing dataset 42 was 14 August 2015, and follow-

Dataset 43

Dataset 43 will be sent to sites in early December. Data entry in REDCap will remain open for enrolment and HCV treatment forms, whereas follow-up forms will re-open in December.

EuroSIDA reimbursements

The annual reimbursement to EuroSIDA sites will be made in November 2015.

EuroSIDA and D:A:D

Please be reminded again that patients enrolled in EuroSIDA cohort 10 are not included in the D:A:D study. **D:A:D event forms should therefore not be completed for cohort 10 patients.** For patients enrolled in earlier EuroSIDA cohorts there are no changes with regards to D:A:D.

REDCap

We have had a number of questions from investigators concerning how to enter the REDCap system. Please be aware that CHIP is working with more than one REDCap system and for EuroSIDA the link to be used is [THIS](#).

HCV Treatment forms in REDCap

Please remember to follow the criteria for completing HCV Treatment forms in REDCap:

- For patients enrolled in cohort 10, the HCV Treatment form should be completed if HCV treatment was ongoing during enrolment or has

up data entry in REDCap is closed until December 2015 when dataset 43 opens.


We are pleased with the return rate as close to 9,500 FU-forms were completed in REDCap. Little more than 2,000 follow-up forms were not completed due to various site issues. 76 centres have completed all or almost all forms.

Enrolment status for the new EuroSIDA cohort

Enrolment will continue until the end of 2015 and we strongly urge those participating centres who have not yet reached their target to **please continue to enroll patients in REDCap as fast as possible**.

Please also remember to complete all sections in the enrolment forms. Cohort 10 patients who have completed enrolment forms before 1 October 2015 can be included in dataset 43.

So far 3,523 patients, **69% of the target of 5,000, have been enrolled**. 78 centres from 31 countries are contributing to the cohort and 38 centres have reached their enrolment target. The EuroSIDA team would like to thank these sites for their professional work done to complete the enrolment process.



PUBLICATIONS

Total number of publications in 2015: 12

Publications since last newsletter August 2015:

HIV resistance testing and detected drug resistance in Europe: Data from the EuroSIDA cohort 1997-2012. A Schultze, AN Phillips, R Paredes, M Battegay, JK Rockstroh, L Machala, J Tomazic, I Januskevica, PM Girard, K Laut, JD Lundgren, A Cozzi-Lepri, on behalf of the EuroSIDA study group in EuroCoord. AIDS. 2015 Jul 17, 29(11): 1379-89

Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. Amit C Achhra; Amanda Mocroft; Peter Reiss; Caroline Sabin; Lene Ryom; Stephane de Wit; Colette J Smith; Antonella d'Arminio Monforte; Andrew Phillips; Rainer Weber; Jens Lundgren; Matthew G Law;

commenced after enrolment (baseline).

- For patients enrolled in EuroSIDA before cohort 10, the HCV Treatment form should be completed if HCV treatment was ongoing 1 June 2014 or has commenced after 1 June 2014.

The HCV Treatment Adverse Event form should be completed if HCV treatment is stopped early due to toxicity/intolerance.

Update from EuroCoord

Please find the latest news from EuroCoord at:

newsletter at www.eurocoord.net



The D:A:D Study Group. HIV Med. 2015 Jul 28. doi: 10.1111/hiv.12294.
[Epub ahead of print]

All publications may be found [HERE](#)

Thank you for a continuous rewarding and succesfull collaboration!

EuroSIDA Coordinating Centre. Rigshospitalet, University of Copenhagen. CHIP, Department of Infectious Diseases, Section
2100, Finsencentret. Blegdamsvej 9, DK-2100 Copenhagen Ø, Denmark.

Tel: +45 35 45 57 57. Fax: +45 35 45 57 58. E-mail: EuroSIDA.rigshospitalet@regionh.dk

Web: www.regionh.dk www.chip.dk

This project has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under EuroCoord grant agreement n° 260694.